NEW YORK (GenomeWeb News) – Millipore said late last night that its board of directors is evaluating "strategic alternatives to enhance shareholder value," including a potential merger or sale of the company.
Millipore's statement comes two days after Bloomberg reported that Thermo Fisher Scientific had made a $6 billion bid for the firm. Millipore did not respond to a request from GenomeWeb Daily News for comment earlier this week, while Thermo Fisher officials said they would not comment on rumors.
Millipore confirmed that it has hired Goldman Sachs as its financial advisor and Cravath, Swaine & Moore as its legal advisor to assist the board in its evaluation.
Millipore also said that it has not set a timetable for completing the evaluation and cannot assure that it will lead to any transaction.
In early Wednesday trade on the New York Stock Exchange, shares of Millipore were up 3 percent at $91.50. Its shares are up 28 percent for the week.